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ABSTRACT 
The solubility of the stable FIII polymorph of the pharmaceutical compound carbamazepine was 
measured by determining its solubility gravimetrically in ethanol and methanol. Where the 
metastable FI polymorph was suspended in a solution of ethanol, the stable FIII polymorph 
nucleated immediately initiating a solution mediated transformation from FI to FIII. This meant 
that the FI polymorph was not in thermodynamic equilibrium with the solution as FI was 
continually dissolving while FIII was growing. We show that the solubility of FI can be 
accurately measured by in situ microscopy using an adaption of the bracketing method and the 
results show that the solubility is close to but higher than the maximum solution concentration 
reached during the solution mediated transformation from FI to FIII carbamazepine in both 
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solvents.  The technique demonstrates a relatively simple and robust method for determining the 
solubility of a metastable crystalline phase which transforms quickly in solution. 
 
INTRODUCTION 
The solubility of a crystalline compound provides vital thermodynamic information required to 
design crystallization processes, engineer the crystal size distribution and understand the phases 
which nucleate in the case of multiple-phase systems. Polymorphs are solid phases of the same 
compound but with different crystal structures. These different crystal structures exist due to the 
different molecular arrangements of the molecules giving rise to differences in free energy and 
thus solubility.
1
 A particular polymorph may have more favourable processing or performance 
characteristics over another. For example, Form II of ranitidine hydrochloride has improved 
filtration properties compared to Form I 
2
 and the orthorhombic polymorph of paracetamol is 
more suitable for compression and tableting than the monoclinic polymorph.
3
 Whether selection 
of a metastable or the stable polymorph is desired for a crystallization process, knowledge of the 
solubility of both phases is critical.  
A thermodynamically stable polymorph will not undergo a transformation and so its solubility 
is readily measured by allowing the crystalline phase to reach equilibrium with the solution, 
provided solvates are not formed in that particular solvent. However, a metastable crystalline 
phase in solution can often quickly transform to a more stable phase
4
 via the process of solution 
mediated transformation, 
5
 a process where the metastable solid phase dissolves and the stable 
phase nucleates and grows independently from solution. The maximum achievable solution 
concentration during such a process is governed by both dissolution of the metastable phase and 
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growth of the stable phase and this can establish a kinetic steady-state for the solution 
concentration. Under such conditions, with the metastable phase dissolving the stable phase 
growing, the metastable phase is not strictly in equilibrium with the solution and so a strict 
measure of the thermodynamic equilibrium concentration for the metastable phase is not 
possible. This kinetic steady-state has been  re iously referred to as “a  arent” solubility, 
because it represents the maximum in concentration reached by dissolution of the metastable 
phase.
6
 The triclinic polymorph (FI) of the pharmaceutical compound carbamazepine (CBZ) is 
an example a metastable phase known to undergo such as solution mediated transformation. The 
FI polymorph quickly transforms to the stable P-monoclinic polymorph (FIII) upon addition to a 
solution of methanol saturated with respect to FIII.
7
  
In practice, measuring the solubility of a crystalline phase (solute) and its variation with 
temperature is typically approached in one of two ways. The system, e.g. solute and solvent, is 
allowed to reach equilibrium at a specific temperature and the concentration of the solute in the 
system is measured via techniques such as gravimetric analysis,
8
 titration,
9
 UV-vis 
spectroscopy,
10
 HPLC 
11
 or solution density.
12
 Alternatively the system is examined for the point 
of equilibrium as a function of temperature, at a specific concentration of components. The latter 
can be achieved with techniques such as the synthetic method,
13
 using differential scanning 
calorimetry (DSC),
14
  in situ infra-red spectroscopy
15
 and microscopic methods.
16
 
In this paper, we present both of these approaches to measuring polymorph solubility. The 
gravimetric method was used to measure the solubility of the stable FIII CBZ polymorph. Due to 
the transformation of the FI polymorph to FIII in bulk experiments where FIII nucleated 
immediately with no induction time, we developed an adaption of the bracketing method 
17
 to 
measure the FI solubility using in situ optical microscopy.   
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EXPERIMENTAL SECTION 
Polymorph Preparation 
Pharmaceutical grade carbamazepine (FIII) having a purity >98% was obtained from 
POLPHARMA S.A. (Starogard Gdański, Poland) and stored in the  resence of silica gel (0% 
humidity). ACS reagent grade ethanol (EtOH) and methanol (MeOH) were used having a purity 
of 99.9% and ≥99.8 %, res ecti ely.  
The FIII polymorph of CBZ was prepared by crystallization from ethanol using an automatic 
lab reactor where 36.9 g of pharmaceutical grade CBZ was dissolved in 393 g of ethanol at 78 
°C. The solution was quickly cooled to 10 °C and aged for 24hrs. The solids were harvested 
using vacuum filtration and dried at 25 °C in a vacuum oven for approximately 40 mins and 
analysed by powder X-ray diffraction (PXRD) using a Panalytical X’Pert MPD PRO X-ray 
diffractometer. To prepare the FI CBZ polymorph, 3 g of FIII CBZ powder was placed on a 
clock glass. This was then placed on aluminium foil and covered by a glass petri dish before 
heating the CBZ powder in the oven at 170°C for 2.5 hrs under full vacuum. Thereafter, the 
pressure was adjusted to ambient and the powder was held for 15-20 mins. The powder was 
allowed to cool slowly to 100°C before removing from the oven and placing in a dessicator to 
reach room temperature. The bulk powder was analysed by PXRD.  Needle-like particles were 
grown on the underside of the pertri dish due to sublimation. Single crystal X-ray diffraction 
(Oxford Diffraction Xcalibur system at ambient temperature) was used to identify the needle-like 
particles as the triclinic FI polymorph of carbamazepine. These were used for measuring the 
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solubility of FI by in situ optical microscopy. Each polymorph was separately imaged using a 
Zeiss axioscope A1m imager optical microscope.  
 
Solubility measurements 
The solubility of FIII in ethanol and methanol respectively was measured by adding excess 
FIII in contact with approx. 30 mL of solvent in a sealed test tube. Isothermal temperature 
control at each temperature was achieved using a thermostatic water bath (Grant GR150, S38 
stainless steel, ±0.02 °C) in which the test tube was placed. Agitation in the test tube was 
provided with the use of a PTFE-coated magnetic stirrer bar. After 24 hrs at each temperature the 
stirring was switched off to allow the suspended solid to settle for 30mins. A solution sample of 
~2 mL was carefully filtered (0.22 μm filter) into a  reweighed  ial and then weighed to 
determine the solution mass. After drying in the fumehood, the vials were transferred to an air 
oven (Binder series VD 53) at 50°C for 24 hrs. The last hour drying was carried out under 
vacuum at ~300mBar. This was to assure perfect dryness and to remove any potential water of 
hydration, as CBZ is known to form a dihydrate structure.
18
 The remaining solute was weighed 
and the concentration was expressed as g of solute/g of solvent. Each solution sample was 
performed in triplicate. Weighing was carried out using a Mettler-Toledo AX054 laboratory 
balance with a readability of 0.1 mg. A solid sample was also vacuum filtered at the time of 
solution sampling and analysed by PXRD to identify the solid phase that was present in 
suspension with the solution.   
An attempt was made to measure the solubility of the metastable FI polymorph of CBZ in the 
same manner as that of FIII. To do this, an excess of FI was suspended in contact with an ethanol 
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solution at 10, 20 and 30 °C respectively. The ethanol was saturated with respect to FIII so as to 
make economic use of FI which was otherwise difficult to produce as a pure polymorph in bulk 
quantities. The mass of FI added in excess at each temperature was equal to the amount of CBZ 
already dissolved to make the solution saturated with respect FIII and as such the mass of FI 
added to each experiment was not the same. The excess FI was added to the clear saturated 
solution of ethanol and CBZ (sealed conical flask - 150mL, magnetic stirring with the same 
thermostatic water bath for isothermal temperature control). At specific time intervals the stirring 
was stopped and suspended solid was allowed to settle for 5mins and a solution sample of ~2 mL 
was carefully filtered and dried as described above to determine the solution concentration in g 
CBZ / g EtOH. Each solution sample was performed in triplicate. At the same time of solution 
sampling a small sample of excess solid (~50mg) was vacuum filtered and analysed by PXRD.  
Microscopic Solubility Measurements 
In order to measure the solubility of FI, we used an experimental set-up previously developed 
(ANACRISMAT) to investigate solution mediated phase transitions of an pharmaceutical 
compound and a protein. 
6, 19
 The set-up consists of a Nikon Diaphot inverted optical microscope 
used in conjunction with an adapted Peltier temperature control unit (±0.1 °C) designed to fit an 
optical holding cell. The optical holding cell was used to hold and seal a quiescent solution 
sample in which a single crystal of FI could be observed. An adaption of the bracketing method 
was used to perform the solubility measurements. 
19
 The bracketing method typically involves 
producing a solution of known concentration/composition and varying the temperature until the 
point of equilibrium is reached where crystals neither dissolve nor grow.
17
 Our adapted 
bracketing method requires examining for the point of equilibrium under isothermal conditions 
where the solution concentration is varied for each experiment. For this method, a temperature 
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was chosen at which to measure the solubility of FI. A solution of known concentration was 
prepared in the holding cell by accurately weighing CBZ and solvent to an approximate volume 
of 2 mL (green point – Figure 1). The cell was heated until the CBZ was dissolved, giving a clear 
solution, and then cooled to the temperature of equilibrium saturation (solubility) with respect to 
FIII (red and blue arrow – Figure 1). The solution was then further cooled to the chosen 
temperature (green arrow – Figure 1), entering a region of the phase diagram supersaturated with 
respect to FIII, and held for ~30mins. Then a single seed crystal of FI was added and monitored 
over time (1 image/min using automated software) for dissolution, growth or no change in 
particle size before the nucleation of the more stable FIII (star point – Figure 1). This procedure 
was repeated for solutions of different concentrations. 
 
 
 Figure 1. Schematic illustration of the adapted bracketing method used to measure the solubility 
of the FI polymorph of CBZ with in situ microscopy. ― Stable FIII solubility, ― putative 
metastable FI solubility →: heat to complete dissolution, ←: cool to saturation and ← cool 
further to the chosen seeding temperature. Stars illustrate different solution concentrations tested 
at the chosen seeding temperature. 
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 The solubility was the average of the concentrations where no change in the particle size of FI 
was observed, before the nucleation of FIII. This method was then repeated to measure the 
solubility of FI at other temperatures. The mass of the FI crystal particle (<10 μg) was negligible 
by comparison to the solution concentration and so it was safe to assume that the solution 
concentration remained constant during growth or dissolution of FI (observable to a resolution of 
10 μm) before the nucleation of FIII. The nucleation and growth of FIII was easily detected in 
the cell by checking the cell for the distinct granular habit of FIII. 
  
 
 
RESULTS AND DISCUSSION  
The bulk polymorph preparation of FI and FIII was analysed by PXRD and compared to the 
theoretical PXRD patterns generated from the .cif files from the Cambridge Crystallographic 
Data Cente (CCDC) – Figure 2. CCDC Database codes: FI – CBMZPN11 and FIII - 
CBMZPN10. The PXRD patterns for each polymorph agree with those reported experimentally 
in the literature 
20
 and with their respective theoretical PXRD patterns. FIII peaks at 15.1 and 
15.4 °2θ were used to check for the  resence of F    in sam les taken from bulk e  eriments 
where FI was suspended in excess with a solution of ethanol and CBZ. The crystal habit of each 
polymorph, identified by optical microscopy, is shown in Figure 3.    
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(A) 
 
(B) 
Figure 2. PXRD of the pure polymorphs FI (A) and FIII (B) of CBZ compared to theoretical 
PXRD pattern generated from the .cif file from the CCDC database. 
 
The single crystal particles grown by sublimation were analysed by single crystal XRD at 
room temperature and identified the crystals as having a triclinic unit cell with lattice parameters: 
a = 5.2728(6), b = 20.6510(3), c = 22.3094(1) Å, α = 84.22(6) °, β = 87.78(1) ° and γ = 84.93(6) 
° confirming the particles as single crystals of FI CBZ.
20
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Figure 3. Optical microscopy used to identify the acicular habit of FI (A) and and granular habit 
of FI   (B).  nset: scale bar 500 μm 
 
The solubility of FIII in ethanol and methanol are presented in Table 1. For each solubility 
measurement, PXRD identified FIII as the only phase present in solution at the time of sampling. 
The temperature was also observed to be accurate to within ±0.05 °C during solution sampling. 
The solubility of FIII increases with temperature in both solvents and agrees well with the 
solubility data of Liu et al. measured for FIII in these solvents using the synthetic method.
13
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Table 1. FIII polymorph solubility data as measured gravimetrically with standard deviations 
(n=3) in the temperature range from 5 – 35 °C. 
T (°C) SOLVENT Solubility  
(g CBZ / g EtOH) 
SOLVENT Solubility  
(g CBZ / g MeOH) 
5.0 Ethanol 0.0155 (±0.0001) Methanol 0.0549 (±0.0004) 
10.0  0.0184 (±0.0003)  0.0630 (±0.0001) 
15.0  0.0217 (±0.0003)  0.0721 (±0.0001) 
20.0  0.0259 (±0.0002)  0.0834 (±0.0001) 
25.0  0.0307 (±0.0004)  0.0970 (±0.0004) 
30.0  0.0363 (±0.0003)  0.1126 (±0.0004) 
35.0  0.0433 (±0.0003)  0.1334 (±0.0004) 
 
 
The results of the bulk experiments that attempted to measure the solubility of FI in ethanol 
gravimetrically at 10, 20 and 30 °C are presented in Figure 4, where excess FI was added at t = 0 
mins and the solution and solid phase were sampled over time. 
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Figure 4. Solution concentration profiles for the attempted measurement of FI solubility in 
ethanol at ♦10 °C, ▲20 °C and ■ 30 °C. The  rofiles indicate the transformation of F  to F    
and the vertical dashed black line indicates where FIII is first detected by PXRD. Lines are 
added as a guide for the eye. 
 
The solution concentration profiles show the solution mediated transformation of FI to FIII in 
ethanol at the different temperatures. As the mass of FI added in excess to each experiment 
varied with temperature the profiles are not directly comparable. The solution concentration at 
the end of the each experiment corresponded to the solubility of FIII in ethanol at each 
temperature previously measured, confirming the transformation to FIII. The transformation was 
also confirmed by the solid samples taken over time which were analysed by PXRD. An example 
of this is shown in Figure 5 for the experiment at 20 °C in ethanol where the transformation of 
the excess suspended solid sampled over time is presented. The presence of FIII in the excess 
solid sam les is detected by the  eaks at 15.1 and 15.4 °2θ corres onding to the (012) and (11-1) 
peaks of FIII, respectively. These peaks are distinct from a very minor (02-3) FI peak at 15.6 
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°2θ. F    was detected in the excess solid after 10 mins (Figure 5B). The presence of FIII was 
also detectable after 10 mins at 10 and 30 °C when FI was suspended in excess in ethanol.  
 
 
Figure 5. The transformation from FI to FIII in the excess suspended solid in ethanol at 20 °C as 
indicated by PXRD. (A) 0 mins – FI, (B) 10mins, (C) 90mins, (D) 150mins – FIII. The vertical 
line indicates the position of the (02-3)  eak of F  at 15.6 °2θ and is distinct from the (012) and 
(11-1)  eaks of F    at 15.1 and 15.4 °2θ, res ecti ely. The FIII peaks at are detectable in (B) 
after 10mins.   
 
The results of Figures 4 and 5 show that the stable FIII polymorph nucleates immediately in 
solution with no detectable induction time in these bulk experiments as FIII was detectable by 
PXRD after only 10 mins. Subsequent solid samples for the solution mediated transformation 
from FI to FIII identified the PXRD peaks associated with FIII to be increasing and those of FI to 
be decreasing until only FIII remains (Figure 5). This reflected a situation whereby the solution 
concentration remained relatively unchanged with the stable FIII growing and the metastable FI 
dissolving, establishing as a kinetic steady-state. Under these conditions, the maximum 
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concentration achievable is dependent on a balance between the overall dissolution and growth 
rates of FI and FIII, respectively. FI is constantly dissolving as FIII grows and FI is not in 
thermodynamic equilibrium with the solution. This is likely to obstruct the strict measurement of 
the thermodynamic equilibrium concentration for the metastable FI polymorph. Recently, the 
solubility of FI in methanol at 10 °C was reported as 0.0874 g (±0.0001) g CBZ / g MeOH in an 
e  eriment  erformed by O’Mahony et al.7 This value was the maximum solution concentration 
measured gravimetrically where excess FI was added to a solution of methanol and where FI 
transformed quickly to FIII with no detectable induction time for the nucleation of FIII (similar 
to the case in ethanol described in Figures 4 and 5).  This reported solubility of FI again 
represents a balance between dissolution of FI and growth of FIII and is not a strict measure of 
the thermodynamic equilibrium concentration of the FI polymorph.  
 
The solvent methanol was chosen for the in situ microscopy experiments to enable the 
solubility of FI to be determined for a number of temperatures in a relatively efficient timeframe. 
CBZ has a higher solubility in methanol relative to ethanol and the processes of growth and 
dissolution (necessary to observe for concentrations outside of the FI equilibrium concentration) 
are generally faster in the solvent with higher solubility.
21 
Using in situ optical microscopy, the 
solubility of FI in methanol was measured by continuously observing a single crystal of FI in a 
solution of known concentration and at a constant temperature, where the variation in 
temperature was observed to be within ±0.1 °C. In conditions where the solution concentration 
was undersaturated with respect to FI, dissolution was evident and when supersaturated with 
respect to FI, growth was evident, before the nucleation of FIII. Some in situ microscopy images 
illustrating these phenomena are presented in Figure 6.  
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Figure 6. In situ optical microscopy images of FI crystal particles before the nucleation of FIII. 
A: no change in particle size (0.0883 g CBZ / g MeOH at 10°C), B: dissolution (0.1352 g CBZ / 
g MeOH at 30°C) and C: growth (0.1568 g CBZ / g MeOH at 30°C).  nset: scale bar 500 μm. 
 
The solubility of FI measured by in situ microscopy using the adapted bracketing method is 
summarised in Table 2.   
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Table 2. FI polymorph solubility data as measured in methanol by in situ microscopy using the 
adapted bracketing method. Standard deviations are included, 10 °C n = 6, 22 °C n = 4 and 30 °C 
n= 3. Also included is the FIII polymorph solubility and chemical potential between FI and FIII 
calculated as RTlnS - product of the gas constant and temperature (K) and the log of the 
solubility ratio (mole fraction) between both polymorphs. 
SOLVENT T (°C) Solubility FI 
(g CBZ / g MeOH) 
Solubility FIII  
(g CBZ / g MeOH) 
RT lnS 
(J/mol) 
Methanol 10.0 0.0940 (±0.0048) 0.0630 (±0.0001) 933.0 
 22.0 0.1221 (±0.0048) 0.0896 (±0.0000)
a
 749.5 
 30.0 0.1480 (±0.0043) 0.1126 (±0.0004) 678.2 
a - the solubility data for FIII at 22 °C in methanol was calculated by interpolation of the data 
in Table 1 
 
The data in Table 2 show that the FI solubility increases with temperature and is greater than 
that of FIII. The chemical potential difference between each polymorph, approximated by 
calculating RTlnS (shown in Table 2), decreases with increasing temperature. This indicates the 
existence of a temperature at which the chemical potential of FI will equal that of FIII, known as 
the thermodynamic transition temperature (Tt) and above this temperature the thermodynamic 
stability order of the polymorphs changes, where FI will be the more stable polymorph. Using a 
straight line approximation, a  an’t Hoff plot of the solubility data of FI and FIII in methanol 
was extrapolated to determine this temperature. A transition temperature of 77 °C was calculated 
from the  an’t Hoff  lot in Figure 7. This tem erature lies below the melt tem erature of all 
polymorphs of CBZ (189-191 °C) 
1
 indicating an enantiotropic relationship between the FI and 
FIII polymorph of CBZ.  
 17 
 
Numerous other studies have attempted to estimate Tt for the FI and FIII polymorphs of CBZ 
based on thermodynamic calculations and/or solubility data in 2-propanol with Tt estimates 
ranging from 71 °C to 96 °C.
14, 22-25
 However, extensive slurry experiments performed by 
Getsoian et al. in cumene for mixtures of FI and FIII CBZ over the range of temperatures 
spanning the estimated Tt has experimentally verified the Tt for FI and FIII polymorphs of CBZ 
to exist between 79-82 °C.
26
 This value agrees well with the Tt of 77 °C calculated for this work.  
 
 
Figure 7.  n e tra olated  an’t Hoff  lot of the solubility (in mole fraction) of F  ● and F    ♦ in 
methanol used to estimate the thermodynamic transition temperature of 77 °C for the 
polymorphs. Data were fitted with linear functions.  
 
 
 18 
The solubility of FI at 10 °C is 0.0940 (±0.0048) g CBZ / g MeOH as measured in Table 2. 
This value is close to but significantly higher than the previously reported solubility value of 
0.0874 (±0.0001) g CBZ / g EtOH measured gravimetrically where a kinetic steady-state was 
established as FIII nucleated with no detectable induction time and FI dissolved while FIII 
grew.
7
 To investigate if this previously reported solubility value, a solution concentration of 
0.0874 g CBZ / g MeOH was prepared and the method with in situ microscopy, previously 
described, was used to examine for growth, dissolution or no change in particle size of FI at 10 
°C in the prepared solution. In Figure 8 time-lapsed in situ microscopy images show the 
dissolution of FI prior to the nucleation and growth of FIII at the surface of FI. The dissolution of 
FI prior to the nucleation of FIII confirmed that the maximum solution concentration achieved 
during the transformation from FI to FIII in methanol at 10 °C 
7
 was below the solubility of FI. 
The nucleation of the stable FIII polymorph at the surface of FI was a common feature observed 
in all microscopy experiments where FIII had nucleated.  
 19 
 
Figure 8. Time-lapsed in situ microscopy images of an FI crystal particle added to a solution of 
methanol (0.0874 g CBZ / g MeOH) at 10 °C. The dissolution evident at the end of the FI 
needle-like particle from 0-40 min is circled, after 63 min FIII nucleated on the surface of FI and 
this is also highlighted. Inset: scale bar 500 μm.    
 
The FI and FIII polymorph solubility ratio, measured in methanol (Table 2), were used to 
calculate the solubility of FI in ethanol.  ssuming the acti ity coefficient, γ, is inde endent of 
small changes in concentration, particularly for a compound with relatively low solubility, the 
approximation was made that the polymorph solubility ratio was independent of the solvent. 
27
 γ 
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was considered constant for the case of a relatively small change in solubility in going from 
methanol to ethanol (approximately 3 times for FIII solubility data – Table 1). The solubility of 
FI in ethanol was calculated using the measured solubility of FIII in ethanol, from Table 1, and 
the solubility ratio in methanol (in mole fraction). The calculation was made by converting the g 
CBZ / g MeOH data for FI and FIII solubility to mole fraction of CBZ and using the solubility 
ratio to calculate the solubility of FI in ethanol, first in mole fraction then in g CBZ / g EtOH. 
The calculated solubility of FI and the measured solubility of FIII in ethanol is presented in 
Figure 9. The maximum solution concentration reached for the attempted gravimetric 
measurement of FI solubility in ethanol (Figure 4) is also indicated in Figure 9. The data indicate 
that the early solution concentrations established during the attempted gravimetric measurement 
of FI solubility (Figure 4) resulted from a kinetic steady-state being established and lies below 
the solubility of FI.  
 
Figure 9. Solubility of FIII CBZ ♦ in ethanol as measured gravimetrically and calculated 
solubility of F  CBZ ● in ethanol. ж marks the maximum solution concentration reached where 
FI was suspended in excess with a solution of ethanol and CBZ – see Figure 4. Data were fitted 
with an exponential function. 
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To examine the validity of the calculated solubility of FI in ethanol, a solution of the same 
concentration as the calculated solubility of FI in ethanol at 30 °C (0.0476 g CBZ / g EtOH) was 
prepared and seeded with a single crystal particle of FI as before. The adapted bracketing 
technique with in situ microscopy previously described was used to examine for growth, 
dissolution or no change in particle size of FI. This solution showed no growth or dissolution 
under the microscope before the nucleation of FIII, confirming that the solution concentration 
was the solubility of FI in ethanol. A solution was prepared having the same concentration as the 
maximum concentration reached in the attempted gravimetric measurement of FI solubility 
(0.0442 g CBZ / g EtOH – see Figure 4) at 30 °C. A single crystal of FI was added to this 
solution and examined for growth, dissolution or no change in particle size of FI. This solution 
showed dissolution of FI before the nucleation of FIII. This result demonstrates that the 
maximum concentration reached for the 30 °C concentration time-profile in Figure 4 where FIII 
nucleated immediately with no induction time is lower than the solubility of FI. As expected, a 
solution prepared with a higher concentration than the calculated solubility of FI (0.0519 g CBZ / 
g EtOH) showed growth of FI under the microscope. 
It is well understood that the presence of a plateau in concentration for the transformation 
profiles in Figure 4 show that the dissolution of FI is faster than the growth of FIII.
5
 This would 
explain why the maximum solution concentration reached during the transformation is close to 
the solubility of FI. However, for a strict measure of the FI solubility, FI must be in equilibrium 
with the solution and this requires balance between dissolution and growth rates occurring at the 
surfaces of the FI crystal. The nucleation and growth of FIII on the surfaces of FI may potentially 
disrupt this balance which may obstruct the solution from reaching thermodynamic equilibrium 
with FI.   
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The absence of the immediate nucleation of FIII for the in situ microscopy measurements is a 
distinct difference compared to the bulk experiments which attempted to measure the FI 
solubility gravimetrically. It is this difference between the methods that facilitates the accurate 
measurement of FI solubility. A more precise measurements of FI solubility may be possible by 
this method if a larger magnification was used to measure the growth or dissolution of a specific 
crystal face.
28
 However, due to the crystallization of FIII at concentrations close to the solubility 
of FI, this approach may prevent the ability to observe FIII nucleation and growth if it does not 
occur on the specific face being observed during the experiments and thus such an approach 
could potentially introduce errors into the FI solubility measurements. Our approach, using lower 
magnifications, presents a robust method for observing FI dissolution, growth or no change in 
crystal particle size while simultaneously checking for the crystallization of the more stable FIII 
polymorph. This has enabled the measurement of the solubility of the FI polymorph of CBZ 
which otherwise quickly transforms under bulk experimental conditions.  
 
CONCLUSION 
The solubility of FIII CBZ was measured gravimetrically in ethanol and methanol. The 
attempted gravimetric measurement of the solubility of FI CBZ in ethanol resulted in the 
immediate nucleation of FIII with no detectable induction time and subsequent transformation to 
FIII - similar to a previous experiment in methanol. An adaption of the bracketing method was 
used with in situ microscopy to measure the solubility of FI CBZ in methanol, before the 
nucleation of FIII. Further investigations using the in situ microscopy method showed that where 
the maximum concentration was reached as FI transforms to FIII in solution and where FIII had 
nucleated with no detectable induction time, this concentration lies close to but below the 
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solubility of FI. By avoiding the immediate nucleation of the stable phase, the use of in situ 
microscopy with the adapted bracketing method described here, demonstrates a relatively simple 
and robust method for determining the solubility of a metastable crystalline phase which readily 
transforms in solution. 
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